WO2016115664A1 - 3d protein-specific monoclonal immunoglobulin a antibodies - Google Patents

3d protein-specific monoclonal immunoglobulin a antibodies Download PDF

Info

Publication number
WO2016115664A1
WO2016115664A1 PCT/CN2015/071021 CN2015071021W WO2016115664A1 WO 2016115664 A1 WO2016115664 A1 WO 2016115664A1 CN 2015071021 W CN2015071021 W CN 2015071021W WO 2016115664 A1 WO2016115664 A1 WO 2016115664A1
Authority
WO
WIPO (PCT)
Prior art keywords
iga
seq
antibodies
igg
antibody
Prior art date
Application number
PCT/CN2015/071021
Other languages
French (fr)
Inventor
Huimin Yan
Moming LI
Dihan ZHOU
Bali ZHAO
Original Assignee
Huimin Yan
Li Moming
Zhou Dihan
Zhao Bali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huimin Yan, Li Moming, Zhou Dihan, Zhao Bali filed Critical Huimin Yan
Priority to PCT/CN2015/071021 priority Critical patent/WO2016115664A1/en
Publication of WO2016115664A1 publication Critical patent/WO2016115664A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Definitions

  • the present invention generally relates to prophylactic and therapeutic agents against enteroviruses, and more particularly to immunoglobulin A (IgA) monoclonal antibodies (mAbs) specific for 3D protein of enteroviruses, and further to prophylactic or therapeutic compositions containing the 3D protein-specific monoclonal IgA antibodies.
  • IgA immunoglobulin A
  • mAbs monoclonal antibodies
  • Enteroviruses are grouped into four major subtypes, A, B, C and D, and each subtype contains many serotypes. Enteroviruses cause diverse diseases. For instance, the major causative agents of hand, foot, and mouth disease (HFMD) are enterovirus 71 (EV71) and coxsackievirus (CV) that belong to the family Picornaviridae. HFMD represents a growing threat to public health, especially for young children. The infection with EV71 and CV causes severe aseptic meningitis, encephalitis, myocarditis, acute faccid paralysis, and pulmonary edema, resulting in high fatality rates.
  • HFMD enterovirus 71
  • CV coxsackievirus
  • EV71 As a member of the genus Enterovirus within the family Picornaviridae, EV71 has a typical positive-sense single stranded RNA genome with a single open reading frame encoding four capsid proteins (VP1-4) and seven nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C and 3D) .
  • 3D (also called 3D pol ) protein acts as a viral RNA-dependent RNA polymerase (RdRp) and plays a major role in viral negative-strand synthesis and the uridylylation of a few proteins.
  • RdRp viral RNA-dependent RNA polymerase
  • the EV71 3D has high sequence identity in all enteroviruses, but has a low homology with human proteins.
  • the EV71 3D generally shares structure/sequence similarity with homologous RdRps from poliovirus, coxsackievirus, rhinovirus and foot-and-mouth disease virus polymerases in Picornaviridae family.
  • 3D has an N-terminal active site.
  • Kiener et al. used a recombinant 3CD protein from EV71 C4 strain as an immunogen and isolated a monoclonal antibody 4B12 (IgG1) recognizing a linear epitope DFEQALFS (corresponding to positions 53-60 of 3D and 1784-1791 of the EV71 polyprotein) close to the active site of the 3D polymerase; 4B12 detected all enterovirus 71 subgenotypes in a denaturing dot blot assay ( Kiener et al. Characterization of a monoclonal antibody against the 3D polymerase of enterovirus 71 and its use for the detection of human enterovirus A infection. J Virol Methods.
  • EV71 vaccine candidates have been investigated, including inactivated EV71 whole virus vaccines, live-attenuated virus vaccine, recombinant VP1 vaccine, VP1-based DNA vaccine, synthetic peptide vaccine and virus-like particle vaccine.
  • Formalin-inactivated EV71 vaccines elicit satisfactory levels of immuoprotection and cross-reactivity neutralization of the antibodies in mice and rhesus monkeys; in China, inactivated EV71 vaccines have completed Phase III clinical trials in 2013. Since the outer capsid contains the major antigenic sites during infection, synthetic peptide vaccines included the peptides only from capsid proteins including VP1 and VP2 ( Kung et al. Update on the development of enterovirus 71 vaccines. Expert Opin Biol Ther. 2014; 3: 1-10) .
  • EV71 is a RNA virus
  • the replication of such EV71 capsid gene by the error-prone RdRp might result in considerable genetic and antigenic diversity.
  • Chen et al. demonstrated that with a panel of monoclonal antibodies against VP1, the genotypes do not reflect their antigenicity, and EV71 viruses could be classified into different antigenic groups (Chen et al. Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine. 2013; 31 (2) : 425-30) . All these demonstrated that it is a challenge for choosing an ideal strain for the development of a vaccine with broad effectiveness.
  • ADE antibody dependent enhancement
  • the anti-sera of P230-323, P646-755, P857-1012 and P1329-1440 showed strong staining with neuron plasma in both adult human cerebra and fetus medulla
  • the anti-sera of P1-69, P324-443, P444-565, P566-665, P746-876, P1441-1526, P1549-1668, P1732-1851 and P2072-2193 showed weaker staining
  • the anti-sera of P70-159, P140-249, P1197-1338, P1649-1731 and P1843-1951 did not show staining with both adult human cerebra and fetus medulla sections.
  • the present invention provides a monoclonal immunoglobulin A (IgA) antibody specifically binding a peptide.
  • the peptide is represented by a consensus sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.
  • the monoclonal IgA antibody binding to the peptide represented by SEQ ID NO: 1 is 3D-2A10-IgA (CCTCC NO: 2014144)
  • the monoclonal IgA antibody binding to the peptide represented by SEQ ID NO: 2 is 3D-3A12-IgA (CCTCC NO: 2014142) .
  • the peptide represented by SEQ ID NO: 1 is selected from the group consisting of the peptides represented by SEQ ID NOS: 3-8, and the peptide represented by SEQ ID NO: 2 is selected from the group consisting of the peptides represented by SEQ ID NOS: 10-14.
  • the present invention also provides a composition comprising at least one first monoclonal immunoglobulin A (IgA) antibody specifically binding to a first peptide represented by a consensus sequence of SEQ ID NO: 1, at least one second monoclonal IgA antibody specifically binding to a second peptide represented by a consensus sequence of SEQ ID NO: 2, and a pharmaceutically acceptable solution.
  • IgA immunoglobulin A
  • the first monoclonal IgA antibody binding to the first peptide represented by SEQ ID NO: 1 is 3D-2A10-IgA (CCTCC NO: 2014144)
  • the second monoclonal IgA antibody binding to the second peptide represented by SEQ ID NO: 2 is 3D-3A12-IgA (CCTCC NO: 2014142) .
  • the first peptide represented by SEQ ID NO: 1 is selected from the group consisting of the peptides represented by SEQ ID NOS: 3-8
  • the second peptide represented by SEQ ID NO: 2 is selected from the group consisting of the peptides represented by SEQ ID NOS: 10-14.
  • FIG. Characterization of EV71 3D-specific monoclonal IgG antibodies.
  • A Pictures showing indirect immunofluorescence staining of EV71-infected cells with 3D-specific IgG mAbs (3A12, 2A10, 7A6G1, and 11F1) ; a flagellin-specific mAb (5G10) was included as a negative control, and 3D-immunized mice serum as positive control.
  • FIG. 3D-specific IgG mAbs intracellularly inhibited EV71 replication (A) A graph showing the virus titers with the presence of intracellular antibodies by transfection. (B) A graph showing the virus titers with the presence of different doses of 2A10 or EV-5. EV-5 is a MAb specific for VP2 of EV71.
  • FIG 3. 3D-specific IgG mAbs inhibited in vitro 3D polymerase activities.
  • A A schematic diagram illustrating 3D (RdRp) -mediated RNA elongation.
  • B A picture showing the effects of different IgG mAbs on 3D-mediated RNA elongation.
  • FIG 4. A graph showing the antiviral efficacies of EV71 3D-specific IgG mAbs in an in vivo murine model.
  • FIG 5. A graph showing the antibody-dependent enhancement of EV71 replication in the presence of 2A10-IgG or EV-5-IgG mAbs.
  • FIG 6. Epitopes of EV71 3D-specific 3A12 and 2A10 and its space situation in three dimension model of EV71 3D (1RA6) .
  • EV71 3D (1RA6) was used to indicate position of the two identified epitopes of 3A12 (orange) and 2A10 (light teal) .
  • FIG 7. Characterization of EV71 3D-specific IgA mAbs.
  • A Pictures showing indirect immunofluorescence staining of EV71-infected cells with 3D-specific IgA mAbs (3A12-IgA and 2A10-IgA) , 16CF7 IgA (anti-MeV) was included as a negative control, and 3D-immunized mice serum as positive control.
  • B Western blot of EV71-infected Vero-1008 cell lysates with 3D-specific IgA mAbs (3A12-IgA and 2A10-IgA; 16CF7 IgA was included as a negative control, and 3D-immunized mice serum as positive control.
  • A A graph showing the virus titers in EV71-infected polarized Vero-pIgR cells with the basolateral presence of IgA antibodies.
  • B A graph showing the virus titers in EV71-infected polarized Vero-pIgR cells with the basolateral presence of different doses of 3A12-IgA or 16CF7 IgA.
  • C A graph showing the virus titers in EV71-infected polarized Vero-pIgR cells with the basolateral presence of different IgG antibodies.
  • D A graph showing the virus titers in EV71-infected polarized Vero C1008 cells with the basolateral presence of different IgA antibodies.
  • FIG 9. EV71 3D-IgA suppressed viral proteins accumulation.
  • A Western blots of detection of 3D and VP2 expression in EV71-infected polarized Vero-pIgR cells with the basolateral presence of IgA antibodies during culture.
  • B A graph showing the ELISA results of detection of 3D and VP2 expression in cells as described in (A) .
  • FIG 10. A picture showing the effects of different IgA mAbs on 3D-mediated RNA elongation.
  • FIG 11. A graph showing the antiviral efficacies of EV71 3D-specific IgA mAbs in an in vivo murine model.
  • FIG 12. Western blot of 3D expression by VTT-3D expression vector (VTT-3D, a attenuated Vaccinia virus expressing 3D) .
  • FIG 13. A diagram showing the immunization and challenge protocol.
  • FIG 14. Graphs showing the 3D-specific antibody responses after prime immunization: (A) serum IgG; (B) serum IgA; (C) saliva IgA; and (D) vagina IgA.
  • FIG 15. Graphs showing the 3D-specific antibody responses after first boost: (A) serum IgG; (B) serum IgA; (C) saliva IgA; and (D) vagina IgA.
  • FIG 16. Graphs showing the 3D-specific antibody responses after second boost: (A) serum IgG; (B) serum IgA; (C) saliva IgA; and (D) vagina IgA.
  • FIG. A graph showing the 3D-specific IgG antibody responses in the intestine of neonatal mice after birth from the immunized mothers.
  • FIG 18. A graph showing the percent survival of the neonatal mice under a mice-adapted strain EV71 challenge.
  • FIG 19. Graphs showing antibody responses after immunization with purified 3D proteins.
  • the present invention discovered that 3D protein-specific monoclonal IgA antibodies were effective in suppressing the replication of enterovirus 71 (EV71) in an in vitro trans-well model and more importantly were capable of protecting host from live challenges.
  • 3D protein of EV71 BrCr strain (SEQ ID NO: 15) was expressed and purified, and purified 3D protein was used to immunized mice for generating monoclonal IgG antibodies following standard protocols.
  • Two 3D-protein specific monoclonal IgG antibodies (3D-2A10-IgG and 3D-3A12-IgG) were generated by conventional hybridoma technology.
  • the corresponding hybridoma cell lines have been deposited at China Center for Type Culture Collections (CCTCC) , CCTCC NO: C2014143 for 3D-2A10-IgG, and CCTCC NO: C2014141 for 3D-3A12-IgG.
  • the monoclonal IgG antibody can be an antibody comprising an Fc domain, a single-chain antibody, or a Fab fragment.
  • the definition and production of the variety of antibodies are well known.
  • hybridoma cell lines for 3D-2A10-IgG and 3D-3A12-IgG were undergone isotype switching; two corresponding monoclonal IgA antibodies (3D-2A10-IgA and 3D-3A12-IgA) were obtained.
  • the corresponding hybridoma cell lines have been deposited at China Center for Type Culture Collections (CCTCC) , CCTCC NO:C2014144 for 3D-2A10-IgA, and CCTCC NO: C2014142 for 3D-3A12-IgA.
  • 3D -3A12-IgA binds to KEPAVLTS (SEQ ID NO: 3)
  • 3D-2A10-IgA binds to YSTYVKDELRSLDKI (SEQ ID NO: 9) .
  • sequence alignment the identified peptides are highly conserved in all enterovirus strains from enterovirus subtypes A, B, C and D.
  • 3D-3A12-IgA binds to a peptide that is represented by a consensus sequence of KEPAVLX 7 X 8 (SEQ ID NO: 1) , where X 7 is selected from the group consisting of T, H, R and N, and X 8 from the group consisting of S, N and K.
  • 3D-2A10-IgA binds to a peptide that is represented by a consensus sequence of X 1 X 2 T X 4 VKDELRSX 12 X 13 KX 15 (SEQ ID NO: 2) , where X 1 is selected from the group consisting of Y, M, L and F, X 2 from the group consisting of S and V, X 4 from the group consisting of Y and F, X 12 from the group consisting of L, A, K and R, X 13 from the group consisting of D, E, T and S, and X 15 from the group consisting of I and V.
  • Enterovirus is comprised of subtypes A, B, C and D.
  • Enterovirus A subtype contains 23 serotypes; the exemplary 3D sequences include: (1) human enterovirus 71 (EV71) , sub-strain BrCr (GenBank AB204852.1) (SEQ ID NO: 15) , where SEQ ID NO: 15 contains the antibody-binding peptides represented by SEQ ID NOS: 3 and 9 respectively; (2) human coxsackievirus A16 strain shzh00-1 (GenBank AY790926.1) (SEQ ID NO: 16) , where SEQ ID NO: 16 contains the antibody-binding peptides represented by SEQ ID NOS: 3 and 9 respectively.
  • Enterovirus B subtype contains 60 serotypes; the exemplary 3D sequences include: (1) human coxsackievirus B3 strain Beijing0811 (GenBank GQ141875.1) (SEQ ID NO: 17) , where SEQ ID NO: 17 contains the antibody-binding peptides represented by SEQ ID NOS: 5 and 10 respectively; (2) human coxsackievirus A9 strain Griggs (GenBank D00627.1) (SEQ ID NO: 18) , where SEQ ID NO: 18 contains the antibody-binding peptides represented by SEQ ID NOS: 5 and 10 respectively.
  • Enterovirus C subtype contains 23 serotypes; the exemplary 3D sequences include: (1) human poliovirus 1 isolate CHN-Jiangxi/89-1 (GenBank: AF111984.2) (SEQ ID NO: 19) , where SEQ ID NO: 19 contains the antibody-binding peptides represented by SEQ ID NOS: 6 and 11 respectively; (2) human coxsackievirus A1 isolate KS-ZPH01F/XJ/CHN/2011 (GenBank: JX174177.1) (SEQ ID NO: 20) , where SEQ ID NO: 20 contains the antibody-binding peptides represented by SEQ ID NOS: 6 and 12 respectively.
  • Enterovirus D subtype contains 5 serotypes; the exemplary 3D sequences include: (1) human enterovirus 68 strain Fermon (GenBank: AY426531.1) (SEQ ID NO: 21) , where SEQ ID NO: 21 contains the antibody-binding peptides represented by SEQ ID NOS: 7 and 13 respectively; (2) human enterovirus 94 isolate E210 (GenBank: DQ916376.1) (SEQ ID NO: 22) , where SEQ ID NO: 22 contains the antibody-binding peptides represented by SEQ ID NOS: 8 and 14 respectively.
  • human enterovirus 68 strain Fermon GenBank: AY426531.1
  • SEQ ID NO: 21 contains the antibody-binding peptides represented by SEQ ID NOS: 7 and 13 respectively
  • human enterovirus 94 isolate E210 GenBank: DQ916376.1
  • SEQ ID NO: 22 contains the antibody-binding peptides represented by SEQ ID NOS: 8 and 14 respectively.
  • Recombinant 3D proteins can be used as immunogens either alone or in combination with other proteins from enteroviruses in immunogenic compositions. As shown in the Examples hereinbelow, 3D protein from EV71 administered together with bacterial flagellin was able to induce antibody responses and partially protect live challenges. Since 3D protein is well conserved in all enteroviruses, it is expected that 3D protein can be used as an immunogen to have broad protections against various subtypes. In addition, certain variants of 3D proteins can also be used in immunogenic compositions, where the identities of these variants in comparison with corresponding wild-type ones are at least 85%, preferably 90%, and more preferably 95%. In addition, the adjuvants may be any known ones such as M59, alum.
  • Antibody compositions for therapeutic uses are well known such as antibodies for cancer treatment.
  • the antibody compositions usually comprise pharmaceutically acceptable ingredients such as sodium chloride dissolved in a pharmaceutically acceptable solution.
  • the present invention demonstrated that 3D-2A10-IgA and 3D-3A12-IgA could protect host from live challenges with a survival rate of 60% (FIG 11) .
  • mice were immunized subcutaneously with 100 ⁇ g 3D at 2-week interval. Four weeks after the last booster and 3 days before cell fusion, the mice were boosted with 200 ⁇ g of 3D i.p. Three days later, murine splenocytes were harvested and fused with SP2/0 using 50% polyethyleneglycol (Sigma-Aldrich, MO) .
  • Hybridoma culture supernatants were screened using ELISA.
  • the positive hybridoma cells were cloned by a limiting dilution and the stable hybridoma clones were injected into liquid paraffin-pretreated abdominal cavities of BALB/c mice. Subsequently, the MAbs were harvested and purified from the seroperitoneum with an antibody purification kit according to the manufacturer’s specifications (NAb TM Protein A/G Spin Kit, Thermo Scientific, USA) .
  • cells were fixed with absolute methanol and processed for indirect immunofluorescence assay (IFA) using indicated 3D-specific MAbs (3A12, 2A10, 7A6G1, and 11F1) , followed by fluorescein isocyanate-conjugated goat anti-mouse IgG antibodies; a flagellin-specific Mab (5G10) was included as a negative control, and 3D-immunized mice serum as positive control.
  • IFA indirect immunofluorescence assay
  • Vero-1008 cells were cultured and infected as above described. Cell lysates were separated by SDS-PAGE, and transferred to PVDF membrane that was blotted by indicated antibodies following conventional western blot protocol. As shown in FIG 1 (B) , lane 1, 3A12; lane 2, 2A10; lane 3, 7A6G1; lane 4, 11F1; lane 5, 5G10 as negative control; and lane 6, positive control. The result showed that 3D protein-specific IgG mAbs (3A12, 2A10, 7A6G1 and 11F1) revealed a specific band corresponding to 3D protein, but negative control (5G10) showed no binding to 3D.
  • EV71-infected cells were obtained and undergone one freeze-thaw cycle, and the virus titers (represented by PFU/well) in these cell samples were titrated by plaque assay.
  • the transfected 3A12 and 2A10 significantly reduced the virus titers; the transfected 7A6G1 reduced the virus titer, but less significant than 3A12 and 2A10; but the transfected 11F1 failed to reduce the virus titer.
  • EV-5 As for EV-5, it was a VP2-specific IgG mAb; the transfected EV-5 failed to reduce the virus titer; it was noteworthy that EV-5, when directly added into cell culture, showed increased virus titer, suggesting an effect of antibody-dependent enhancement (ADE) .
  • ADE antibody-dependent enhancement
  • Vero-1008 cells were cultured and infected and treated with antibodies as above described except for the doses of antibodies.
  • the transfected 2A10 exhibited a dose-dependent inhibitory effect on the reduction of virus titers within the tested doses (0, 0.2, 1 or 5 ⁇ g/well) , but the transfected EV-5 showed no inhibition at all tested doses.
  • Three independent experiments were performed in duplicate, and the representative data were presented.
  • FIG 3 (A) there is provided a schematic diagram of 3D (RdRp) -mediated RNA elongation.
  • RNA elongation activity of 3D could be determined based on the appearance of elongated RNA band. As shown in FIG 3 (B) , lane 1, negative control without polymerase; lane 2, positive control (no interventional factor) ; lane 3, 3A12; lane 4, 2A10; lane 5, 7A6G1; lane 6, 11F1; and lane 7, EV-5.
  • mice 30 one-day old neonatal mice were randomly divided into 6 groups (5 mice per group) . Each group received, ip, 100 ⁇ g/50 ⁇ l 3A12, 2A10, 7A6G1, 11F1 or EV-5 IgG antibodies respectively, and PBS group was include as negative control; then each group received 10 3 TCID 50 EV71 challenge i.p. And IgG was injected with 24-hours interval for 4 times. The mice survival data were collected each day for 2 weeks. As shown in FIG 4, 2A10-IgG and 3A12-IgG conferred 20% or 40% protection respectively.
  • EV71 1 ⁇ 10 4 PFU EV71 were added to the consecutively diluted 200 ⁇ l mAbs (EV-5 IgG for EV71 VP2, or 2A10-IgG for EV71 3D) .
  • the mixture infected the Caco-2 cell after 1 hour incubation.
  • the EV71-infected Caco-2 cells were harvested, and the virus titers in these cell samples were titrated by plaque assay.
  • EV-5 significantly enhanced the viral infection under the concentrations between 0.25-16 ⁇ g/ml compared with the baseline (P ⁇ 0.01) , but 2A10 did not enhance the viral infection at all tested doses.
  • 3D gene encoded protein represented in SEQ ID NO: 15
  • its truncated mutants were cloned into the pET28a expression vector, and the binding activity of IgAs to 3D protein and mutants was determined by Western blot. Furthermore, synthesized distinct lengths of peptides were used to identify the exact domain recognized by 3A12 and 2A10. As shown in Table 1, 3A12 and 2A10 recognized the polypeptides: KEPAVLTS (SEQ ID NO: 3) and YSTYVKDELRSLDKI (SEQ ID NO: 9) , respectively.
  • 2A10-IgA and 3A12-IgA mAbs were respectively obtained by isotype switching from 2A10-IgG and 3A12-IgG mAbs following conventional isotype switching techniques.
  • cells were fixed with absolute methanol and processed for indirect immunofluorescence assay (IFA) using indicated 3D-specific IgA mAbs (3A12-IgA, 2A10-IgA) , negative control (16CF7-IgA against MeV) or positive control (3D-immunized mice serum) , followed by fluorescein isocyanate-conjugated goat anti-mouse IgA for determining antibody specificity against EV71.
  • 3A12-IgA and 2A10-IgA, as well as positive serum could interact with EV71-infected cell, but negative control showed negative staining.
  • EV71-infected VERO-C1008 cells were lysed and the cell lysates were separated by SDS-PAGE, and transferred to PVDF membrane that was blotted with 3A12-IgA, 2A10-IgA, 16CF7-IgA and positive sera.
  • 3A12-IgA and 2A10-IgA mAbs maintained the 3D-specificity of 3A12-IgG and 2A10-IgG mAbs respectively.
  • Polarized Vero-pIgR cells were cultured in Transwell with 0.4 ⁇ m membrance and infected by EV71, allowing virus to be absorbed by the Vero-pIgR cells (virus attachment) .
  • Vero-pIgR cells were washed at both apical and basolateral sides to remove non-absorbed viruses.
  • 400 ⁇ l of complete DMEM was added to apical side; and 3D-specific or irrelative IgA antibodies (30 ⁇ g IgA in 110 ⁇ l) were added to the basolateral side, allowing the IgA antibodies to undergo transcytosis from basolateral side to apical side of the polarized Vero-pIgR cells.
  • Vero-pIgR cells were washed thoroughly with PBS at both sides and scraped with 400 ⁇ l complete DMED, and the virus titers in these cell samples were titrated by plaque assay. As shown in FIG 8 (A) , both 3A12-IgA and 2A10-IgA significantly inhibited EV71 replication while 16CF7-IgA did not show inhibition.
  • Vero-pIgR cells in (i) were replaced by Vero C1008 cells.
  • all three IgA antibodies (3A12-IgA, 2A10-IgA and 16CF7-IgA) showed no significant inhibitory effect on EV71 replication, indicating that IgA-mediated intracellular inhibition of EV71 replication is dependent upon the expression of pIgR on vero cell surfaces.
  • Polarized Vero-pIgR cells were cultured in Transwell with 0.4 ⁇ m membrance and infected by EV71, allowing virus to absorb the Vero-pIgR cells (virus attachment) .
  • Vero-pIgR cells were washed at both apical and basolateral sides to remove non-absorbed viruses.
  • 400 ⁇ l of complete DMEM was added to apical side; and 3D-specific or irrelative IgA antibodies (30 ⁇ g IgA in 110 ⁇ l) were added to the basolateral side, allowing the IgA antibodies to undergo transcytosis from basolateral side to apical side of the polarized Vero-pIgR cells.
  • Vero-pIgR cells were washed thoroughly with PBS at both sides and scraped with 400 ⁇ l complete DMED, and these cell samples were assessed for the quantities of proteins 3D and VP2 by western blot.
  • 3A12-IgA (lane 1) and 2A10-IgA (lane 2) significantly inhibited the expression of 3D and VP2, but 16CF7-IgA (lane 3) and DMEM (lane 4) had no apparent inhibition.
  • RNA elongation activity of 3D could be judged based on the appearance of elongated RNA band.
  • lane 1 negative control with no polymerase added; lane 2, positive control (no interventional factor) ; lane 3, 16CF7-IgA (2 ⁇ g) ; lane 4, 2A10-IgA (2 ⁇ g) ; lane 5, 3A12-IgA (2 ⁇ g) .
  • RNA elongation activity of 3D could be judged based on the appearance of elongated RNA band.
  • the application of MAbs IgA 2A10 and 3A12 significantly suppressed the appearance of elongated when compared with 16CF7-IgA (irrelative anti-MeV IgA) .
  • Three independent experiments were performed, and the representative data were presented.
  • mice All the one day-neonatal mice received 100 ⁇ g/50 ⁇ l IgA i.p. followed by 1000TCID 50 EV71 virus challenge i.p. And IgA was injected with 24h interval for 4 times. The mice survival data was collected each day for 3 weeks. As shown in FIG 11, 2A10-IgA and 3A12-IgA conferred 40% and 60% protection respectively.
  • EV71 3D was detected in recombinant Vaccinia Virus-infected Vero cells.
  • Lane 1 protein molecular weight marker, lane 2, mock infected Vero control, lane 3, VTTenv infected Vero, lane 4-7, four purified recombinant Vaccinia Virus clone-infected Vero.
  • the infected or non-infected Vero were separated by SDS-PAGE, and transferred to PVDF membrane.
  • 3D-specific IgG mAb 2A10-IgG was used as binding antibody. The result show that 3D gene inserted into Vaccinia Virus genome and expressed correctly in Vero cell.
  • FIG 13 there is provided a schematic diagram showing the immunization protocol.
  • Antibody responses were assayed after each immunization: prime (FIG 14) ; first boost (FIG 15) ; second boost (FIG 16) .
  • prime (FIG 14) ; first boost (FIG 15) ; second boost (FIG 16) .
  • Each mouse in VTT-3D group received immunization of 10 7 PFU of virus in 100 ⁇ l, whereas each mouse in 3D group was subject to be immunized with 30 ⁇ g 3D protein in 100 ⁇ l.
  • Serum and mucosal samples from vagina and saliva were collected and subject to determine the titer of IgA against 3D protein by ELISA.
  • mice in VTT-3D group, 3D group, PBS groups as well as inactivated EV71 group were challenged with 10 3 TCID50 of virus. Neonatal mouse was observed each day. Inactivated EV71 immunization conferred complete protection of mice. All the mice in PBS negative control died in 3-5 days after challenge. As shown in FIG 18, 3D and VTT-3D conferred mice 10%-30% protection from challenge.
  • 3D protein was expressed in Example 1.1.
  • Purified 3D protein was adjuvanted with flagellin from E coli. or CTB, and then immunized mice subcutaneously (SC) , intranasally (IN) or intraperitoneally (IP) .
  • SC subcutaneously
  • I intranasally
  • IP intraperitoneally
  • the immunization protocol was summarized in Table 4. The intervals between two immunizations were 2 weeks; the volumes for SC and IP were 100 ⁇ l, while the volumes for IN were 20 ⁇ l.
  • FIG 19 shows the titers of 3D-specific IgG antibodies in serum (a) , lung (b) and intestine (c) , and 3D-specific IgA antibodies in serum (d) , lung (e) and intestine (f) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided is a monoclonal immunoglobulin A (IgA) antibody specifically binding to a peptide represented by a consensus sequence selected from SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a composition comprising at least one first monoclonal IgA antibody specifically binding to the first peptide represented by a consensus sequence of SEQ ID NO: 1, at least one second monoclonal IgA antibody specifically binding to the second peptide represented by a consensus sequence of SEQ ID NO: 2, and a pharmaceutically acceptable solution.

Description

3D PROTEIN-SPECIFIC MONOCLONAL IMMUNOGLOBULIN A ANTIBODIES Field of the Invention
The present invention generally relates to prophylactic and therapeutic agents against enteroviruses, and more particularly to immunoglobulin A (IgA) monoclonal antibodies (mAbs) specific for 3D protein of enteroviruses, and further to prophylactic or therapeutic compositions containing the 3D protein-specific monoclonal IgA antibodies.
Background of the Invention
Enteroviruses are grouped into four major subtypes, A, B, C and D, and each subtype contains many serotypes. Enteroviruses cause diverse diseases. For instance, the major causative agents of hand, foot, and mouth disease (HFMD) are enterovirus 71 (EV71) and coxsackievirus (CV) that belong to the family Picornaviridae. HFMD represents a growing threat to public health, especially for young children. The infection with EV71 and CV causes severe aseptic meningitis, encephalitis, myocarditis, acute faccid paralysis, and pulmonary edema, resulting in high fatality rates.
As a member of the genus Enterovirus within the family Picornaviridae, EV71 has a typical positive-sense single stranded RNA genome with a single open reading frame encoding four capsid proteins (VP1-4) and seven nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C and 3D) . 3D (also called 3Dpol) protein acts as a viral RNA-dependent RNA polymerase (RdRp) and plays a major role in viral negative-strand synthesis and the uridylylation of a few proteins. From the studies of the crystal structure of EV71, one EV71 virion contains an outer capsid  formed by 60 copies each of three viral structural proteins VP1-VP3 and the inner surface of the capsid is attached by 60 copies of a small protein VP4.
3D has high sequence identity in all enteroviruses, but has a low homology with human proteins. The EV71 3D generally shares structure/sequence similarity with homologous RdRps from poliovirus, coxsackievirus, rhinovirus and foot-and-mouth disease virus polymerases in Picornaviridae family.
3D has an N-terminal active site. Kiener et al. used a recombinant 3CD protein from EV71 C4 strain as an immunogen and isolated a monoclonal antibody 4B12 (IgG1) recognizing a linear epitope DFEQALFS (corresponding to positions 53-60 of 3D and 1784-1791 of the EV71 polyprotein) close to the active site of the 3D polymerase； 4B12 detected all enterovirus 71 subgenotypes in a denaturing dot blot assay (Kiener et al. Characterization of a monoclonal antibody against the 3D polymerase of enterovirus 71 and its use for the detection of human enterovirus A infection. J Virol Methods. 2012； 180 (1-2) : 75-83) . The detection of broad subgenotype strains by 4B12 strongly suggested that 3D-specific mAb might be useful for diagnostic of infection, but no prophylactic or therapeutic use of 4B12 has ever mentioned or suggested, let alone general 3D-specific antibodies.
Since vaccine is the best strategy to control the infectious diseases, various EV71 vaccine candidates have been investigated, including inactivated EV71 whole virus vaccines, live-attenuated virus vaccine, recombinant VP1 vaccine, VP1-based DNA vaccine, synthetic peptide vaccine and virus-like particle vaccine. Formalin-inactivated EV71 vaccines elicit satisfactory levels of immuoprotection and cross-reactivity neutralization of the antibodies in mice and rhesus monkeys； in China, inactivated EV71 vaccines have completed Phase III clinical trials in 2013. Since the outer capsid contains the major antigenic sites during infection, synthetic peptide vaccines included the peptides only from capsid proteins including VP1 and VP2 (Kung et al. Update on the development of enterovirus 71 vaccines. Expert Opin Biol  Ther. 2014； 3: 1-10) .
Because EV71 is a RNA virus, the replication of such EV71 capsid gene by the error-prone RdRp might result in considerable genetic and antigenic diversity. Chen et al. demonstrated that with a panel of monoclonal antibodies against VP1, the genotypes do not reflect their antigenicity, and EV71 viruses could be classified into different antigenic groups (Chen et al. Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine. 2013； 31 (2) : 425-30) . All these demonstrated that it is a challenge for choosing an ideal strain for the development of a vaccine with broad effectiveness.
Since no vaccine or specific antiviral is currently available, human intraveneous immunoglobulin (IVIG) has been clinically used in treating severe EV71 infections. However, the discovery of antibody dependent enhancement (ADE) of EV71 infection illustrates the complex roles of antibody in controlling EV71 infection. ADE is a phenomenon in which preexisting sub-levels of neutralizing antibodies enhance virus entry and replication. Sub-levels of neutralizing antibodies was evidenced to enhance EV71 infection in Fc receptor-bearing human monocytes and contributed to exacerbation of EV71 infection in mice. Furthermore, the wide existence of cross reactivity between enterovirus antibodies may also become the underlying risk for the ADE during EV71 infections.
Han et al. demonstrated that lower concentration (50μg/ml) of neutralizing antibodies (IVIG) against EV71 can enhance EV71 infection in a monocytic cell line (Han et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J. 2011； 8: 106) . Cao et al. further studied the roles of each IgG subclass on neutralization and enhancement of EV71 infection, and found that the neutralizing activity of human IVIG is mainly mediated by IgG1 subclass and to less extent by IgG2 subclass, and IgG3 fraction did not have neutralizing activity but enhanced EV71 infection in vitro (Cao et al., Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One. 2013； 8 (5) : e64024) . Therefore, novel vaccine  should be designed to induce the production of antibodies with strong neutralizing but weaker ADE activities.
Since structural capsid proteins have antigenic diversity due to mutations, it is difficult to identify universal antibodies against them； so far, two universal IgG monoclonal antibodies have been identified, one against VP1 (Lim et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One. 2012； 7 (1) : e29751) , and another against VP3 (Kiener et al. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein. PLoS Negl Trop Dis. 2014； 8 (5) : e2895) . However, the ADE capacity of these universal antibodies was not studied.
Serious safety concerns for the inactivated EV71 virus vaccines have been raised by the studies of Jia et al (Jia et al. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J. 2010； 7: 47) . Jia et al. showed the presence of specific IgG in the EV71 infected patient sera having the cross-reactivity activity to human cerebra； then using 19 purified peptides to prepare polyclonal sera, the anti-sera of P230-323, P646-755, P857-1012 and P1329-1440 showed strong staining with neuron plasma in both adult human cerebra and fetus medulla, the anti-sera of P1-69, P324-443, P444-565, P566-665, P746-876, P1441-1526, P1549-1668, P1732-1851 and P2072-2193 showed weaker staining, and the anti-sera of P70-159, P140-249, P1197-1338, P1649-1731 and P1843-1951 did not show staining with both adult human cerebra and fetus medulla sections.
Therefore, there is an imperative need to develop new means against enteroviruses such as EV71 and CV causing HFMD.
Summary of the Invention
The present invention provides a monoclonal immunoglobulin A (IgA) antibody specifically binding a peptide. In one embodiment, the peptide is  represented by a consensus sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.
In another embodiment of the monoclonal IgA antibody, the monoclonal IgA antibody binding to the peptide represented by SEQ ID NO: 1 is 3D-2A10-IgA (CCTCC NO: 2014144) , and the monoclonal IgA antibody binding to the peptide represented by SEQ ID NO: 2 is 3D-3A12-IgA (CCTCC NO: 2014142) .
In another embodiment of the monoclonal IgA antibody, the peptide represented by SEQ ID NO: 1 is selected from the group consisting of the peptides represented by SEQ ID NOS: 3-8, and the peptide represented by SEQ ID NO: 2 is selected from the group consisting of the peptides represented by SEQ ID NOS: 10-14.
The present invention also provides a composition comprising at least one first monoclonal immunoglobulin A (IgA) antibody specifically binding to a first peptide represented by a consensus sequence of SEQ ID NO: 1, at least one second monoclonal IgA antibody specifically binding to a second peptide represented by a consensus sequence of SEQ ID NO: 2, and a pharmaceutically acceptable solution.
In another embodiment of the composition, the first monoclonal IgA antibody binding to the first peptide represented by SEQ ID NO: 1 is 3D-2A10-IgA (CCTCC NO: 2014144) , and the second monoclonal IgA antibody binding to the second peptide represented by SEQ ID NO: 2 is 3D-3A12-IgA (CCTCC NO: 2014142) .
In another embodiment of the composition, the first peptide represented by SEQ ID NO: 1 is selected from the group consisting of the peptides represented by SEQ ID NOS: 3-8, and the second peptide represented by SEQ ID NO: 2 is selected from the group consisting of the peptides represented by SEQ ID NOS: 10-14.
The objectives and advantages of the invention will become apparent from the following detailed description of preferred embodiments thereof in connection with the accompanying drawings.
Brief Description of the Drawings
Preferred embodiments according to the present invention will now be described with reference to the Figures, in which like reference numerals denote like elements.
FIG 1. Characterization of EV71 3D-specific monoclonal IgG antibodies. (A) Pictures showing indirect immunofluorescence staining of EV71-infected cells with 3D-specific IgG mAbs (3A12, 2A10, 7A6G1, and 11F1) ； a flagellin-specific mAb (5G10) was included as a negative control, and 3D-immunized mice serum as positive control. (B) Western blot of EV71-infected Vero-1008 cell lysates with 3D-specific IgG mAbs (3A12, 2A10, 7A6G1, and 11F1) ； a flagellin-specific mAb (5G10) was included as a negative control, and 3D-immunized mice serum as positive control.
FIG 2. 3D-specific IgG mAbs intracellularly inhibited EV71 replication. (A) A graph showing the virus titers with the presence of intracellular antibodies by transfection. (B) A graph showing the virus titers with the presence of different doses of 2A10 or EV-5. EV-5 is a MAb specific for VP2 of EV71.
FIG 3. 3D-specific IgG mAbs inhibited in vitro 3D polymerase activities. (A) A schematic diagram illustrating 3D (RdRp) -mediated RNA elongation. (B) A picture showing the effects of different IgG mAbs on 3D-mediated RNA elongation.
FIG 4. A graph showing the antiviral efficacies of EV71 3D-specific IgG mAbs in an in vivo murine model.
FIG 5. A graph showing the antibody-dependent enhancement of EV71 replication in the presence of 2A10-IgG or EV-5-IgG mAbs.
FIG 6. Epitopes of EV71 3D-specific 3A12 and 2A10 and its space situation in three dimension model of EV71 3D (1RA6) . EV71 3D (1RA6) was used to indicate position of the two identified epitopes of 3A12 (orange) and 2A10 (light teal) .
FIG 7. Characterization of EV71 3D-specific IgA mAbs. (A) Pictures showing indirect immunofluorescence staining of EV71-infected cells with 3D-specific IgA mAbs (3A12-IgA and 2A10-IgA) , 16CF7 IgA (anti-MeV) was included as a negative control, and 3D-immunized mice serum as positive control. (B) Western blot of EV71-infected Vero-1008 cell lysates with 3D-specific IgA mAbs (3A12-IgA and 2A10-IgA； 16CF7 IgA was included as a negative control, and 3D-immunized mice serum as positive control.
FIG 8. 3D-specific IgA mAbs intracellularly inhibited EV71 replication. (A) A graph showing the virus titers in EV71-infected polarized Vero-pIgR cells with the basolateral presence of IgA antibodies. (B) A graph showing the virus titers in EV71-infected polarized Vero-pIgR cells with the basolateral presence of different doses of 3A12-IgA or 16CF7 IgA. (C) A graph showing the virus titers in EV71-infected polarized Vero-pIgR cells with the basolateral presence of different IgG antibodies. (D) A graph showing the virus titers in EV71-infected polarized Vero C1008 cells with the basolateral presence of different IgA antibodies.
FIG 9. EV71 3D-IgA suppressed viral proteins accumulation. (A) Western blots of detection of 3D and VP2 expression in EV71-infected polarized Vero-pIgR cells with the basolateral presence of IgA antibodies during culture. (B) A graph showing the ELISA results of detection of 3D and VP2 expression in cells as described in (A) .
FIG 10. A picture showing the effects of different IgA mAbs on 3D-mediated RNA elongation.
FIG 11. A graph showing the antiviral efficacies of EV71 3D-specific IgA mAbs in an in vivo murine model.
FIG 12. Western blot of 3D expression by VTT-3D expression vector (VTT-3D, a attenuated Vaccinia virus expressing 3D) .
FIG 13. A diagram showing the immunization and challenge protocol.
FIG 14. Graphs showing the 3D-specific antibody responses after prime immunization: (A) serum IgG； (B) serum IgA； (C) saliva IgA； and (D) vagina IgA.
FIG 15. Graphs showing the 3D-specific antibody responses after first boost: (A) serum IgG； (B) serum IgA； (C) saliva IgA； and (D) vagina IgA.
FIG 16. Graphs showing the 3D-specific antibody responses after second boost: (A) serum IgG； (B) serum IgA； (C) saliva IgA； and (D) vagina IgA.
FIG 17. A graph showing the 3D-specific IgG antibody responses in the intestine of neonatal mice after birth from the immunized mothers.
FIG 18. A graph showing the percent survival of the neonatal mice under a mice-adapted strain EV71 challenge.
FIG 19. Graphs showing antibody responses after immunization with purified 3D proteins.
Detailed Description of the Invention
The present invention may be understood more readily by reference to the following detailed description of certain embodiments of the invention.
Throughout this application, where publications are referenced, the disclosures of these publications are hereby incorporated by reference, in their entireties, into this application in order to more fully describe the state of art to which this invention pertains.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques) , microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, for example, Molecular Cloning: A Laboratory Mannual, second edition (Sambrook et al., 1989) ； Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987) .
The present invention discovered that 3D protein-specific monoclonal IgA antibodies were effective in suppressing the replication of enterovirus 71 (EV71) in an in vitro trans-well model and more importantly were capable of protecting host from live challenges.
3D protein of EV71 BrCr strain (SEQ ID NO: 15) was expressed and purified, and purified 3D protein was used to immunized mice for generating monoclonal IgG antibodies following standard protocols. Two 3D-protein specific monoclonal IgG antibodies (3D-2A10-IgG and 3D-3A12-IgG) were generated by conventional hybridoma technology. The corresponding hybridoma cell lines have been deposited at China Center for Type Culture Collections (CCTCC) , CCTCC NO: C2014143 for 3D-2A10-IgG, and CCTCC NO: C2014141 for 3D-3A12-IgG. The monoclonal IgG antibody can be an antibody comprising an Fc domain, a single-chain antibody, or a Fab fragment. The definition and production of the variety of antibodies are well known.
The hybridoma cell lines for 3D-2A10-IgG and 3D-3A12-IgG were undergone isotype switching； two corresponding monoclonal IgA antibodies (3D-2A10-IgA and 3D-3A12-IgA) were obtained. The corresponding hybridoma cell lines have been deposited at China Center for Type Culture Collections (CCTCC) , CCTCC NO:C2014144 for 3D-2A10-IgA, and CCTCC NO: C2014142 for 3D-3A12-IgA.
Using recombinant 3D proteins with sequential deletions from either ends, the binding peptides for antibodies were identified. As expected from the binding specificities of the corresponding IgG antibodies, 3D -3A12-IgA binds to KEPAVLTS (SEQ ID NO: 3) , and 3D-2A10-IgA binds to YSTYVKDELRSLDKI (SEQ ID NO: 9) . Using sequence alignment, the identified peptides are highly conserved in all enterovirus strains from enterovirus subtypes A, B, C and D. As shown in Table 1 hereinbelow, 3D-3A12-IgA binds to a peptide that is represented by a consensus sequence of KEPAVLX7X8 (SEQ ID NO: 1) , where X7 is selected from the group consisting of T, H, R and N, and X8 from the group consisting of S, N and K. 3D-2A10-IgA binds to a peptide that is represented by a consensus sequence of X1X2T X4VKDELRSX12X13KX15 (SEQ ID NO: 2) , where X1 is selected from the group consisting of Y, M, L and F, X2 from the group consisting of S and V, X4 from the group consisting of Y and F, X12 from the group consisting of L, A, K and R, X13  from the group consisting of D, E, T and S, and X15 from the group consisting of I and V.
Table 1. Consensus sequences and exemplary sequences recognized by 3D-2A10-IgA or 3D-3A12-IgA
Figure PCTCN2015071021-appb-000001
Enterovirus is comprised of subtypes A, B, C and D.
Enterovirus A subtype contains 23 serotypes； the exemplary 3D sequences include: (1) human enterovirus 71 (EV71) , sub-strain BrCr (GenBank AB204852.1) (SEQ ID NO: 15) , where SEQ ID NO: 15 contains the antibody-binding  peptides represented by SEQ ID NOS: 3 and 9 respectively； (2) human coxsackievirus A16 strain shzh00-1 (GenBank AY790926.1) (SEQ ID NO: 16) , where SEQ ID NO: 16 contains the antibody-binding peptides represented by SEQ ID NOS: 3 and 9 respectively.
Enterovirus B subtype contains 60 serotypes； the exemplary 3D sequences include: (1) human coxsackievirus B3 strain Beijing0811 (GenBank GQ141875.1) (SEQ ID NO: 17) , where SEQ ID NO: 17 contains the antibody-binding peptides represented by SEQ ID NOS: 5 and 10 respectively； (2) human coxsackievirus A9 strain Griggs (GenBank D00627.1) (SEQ ID NO: 18) , where SEQ ID NO: 18 contains the antibody-binding peptides represented by SEQ ID NOS: 5 and 10 respectively.
Enterovirus C subtype contains 23 serotypes； the exemplary 3D sequences include: (1) human poliovirus 1 isolate CHN-Jiangxi/89-1 (GenBank: AF111984.2) (SEQ ID NO: 19) , where SEQ ID NO: 19 contains the antibody-binding peptides represented by SEQ ID NOS: 6 and 11 respectively； (2) human coxsackievirus A1 isolate KS-ZPH01F/XJ/CHN/2011 (GenBank: JX174177.1) (SEQ ID NO: 20) , where SEQ ID NO: 20 contains the antibody-binding peptides represented by SEQ ID NOS: 6 and 12 respectively.
Enterovirus D subtype contains 5 serotypes； the exemplary 3D sequences include: (1) human enterovirus 68 strain Fermon (GenBank: AY426531.1) (SEQ ID NO: 21) , where SEQ ID NO: 21 contains the antibody-binding peptides represented by SEQ ID NOS: 7 and 13 respectively； (2) human enterovirus 94 isolate E210 (GenBank: DQ916376.1) (SEQ ID NO: 22) , where SEQ ID NO: 22 contains the antibody-binding peptides represented by SEQ ID NOS: 8 and 14 respectively.
Recombinant 3D proteins can be used as immunogens either alone or in combination with other proteins from enteroviruses in immunogenic compositions. As shown in the Examples hereinbelow, 3D protein from EV71 administered together with bacterial flagellin was able to induce antibody responses and partially protect live challenges. Since 3D protein is well conserved in all enteroviruses, it is expected  that 3D protein can be used as an immunogen to have broad protections against various subtypes. In addition, certain variants of 3D proteins can also be used in immunogenic compositions, where the identities of these variants in comparison with corresponding wild-type ones are at least 85％, preferably 90％, and more preferably 95％. In addition, the adjuvants may be any known ones such as M59, alum.
Since the antibodies against 3D proteins do not show ADE effect, it is advantageous to use an antibody composition to treat patients for enterovirus infection. Antibody compositions for therapeutic uses are well known such as antibodies for cancer treatment. The antibody compositions usually comprise pharmaceutically acceptable ingredients such as sodium chloride dissolved in a pharmaceutically acceptable solution. The present invention demonstrated that 3D-2A10-IgA and 3D-3A12-IgA could protect host from live challenges with a survival rate of 60％ (FIG 11) .
The following examples are provided for the sole purpose of illustrating the principles or implementation of the present invention； they are by no means intended to limit or narrow the scope of the present invention.
Example 1
EV71 3D-specific IgG monoclonal antibodies
1.1. Antigen preparation
Complete 3D gene (encoded protein as shown in SEQ ID NO: 15) of EV71 BrCr strain was cloned into vector pET28a with NcoI and XhoI. Briefly, the transformed bacteria E. coli BL21 (DE3) containing recombinant 3D expression constructs were grown and induced. These recombinant proteins were prepared and purified by affinity chromatography on a Ni-NTA column (Qiagen) . It is to be noted that 3D and 3D are used in this application interchangeably.
1.2. Immunization and production of EV71 3D-specific IgG monoclonal antibodies
The method for generating EV71 3D-specific mAbs was as previously described (Li YM, Liu F, Han C and Yan HM. Monoclonal antibody that blocks the Toll-like receptor 5 binding region of flagellin. Hybridoma (Larchmt) . 2012  Feb； 31 (1) : 60-62) . Briefly, 5-week-old female SPF BALB/c mice were immunized subcutaneously with 100μg 3D at 2-week interval. Four weeks after the last booster and 3 days before cell fusion, the mice were boosted with 200μg of 3D i.p. Three days later, murine splenocytes were harvested and fused with SP2/0 using 50％ polyethyleneglycol (Sigma-Aldrich, MO) . Hybridoma culture supernatants were screened using ELISA. The positive hybridoma cells were cloned by a limiting dilution and the stable hybridoma clones were injected into liquid paraffin-pretreated abdominal cavities of BALB/c mice. Subsequently, the MAbs were harvested and purified from the seroperitoneum with an antibody purification kit according to the manufacturer’s specifications (NAbTM Protein A/G Spin Kit, Thermo Scientific, USA) .
1.3. Verification of the binding specificities of 3D-specific IgG mAbs
Vero-1008 cells in 24-well plate were infected with EV71 (MOI ＝ 0.1) . At 24 hours post-infection, cells were fixed with absolute methanol and processed for indirect immunofluorescence assay (IFA) using indicated 3D-specific MAbs (3A12, 2A10, 7A6G1, and 11F1) , followed by fluorescein isocyanate-conjugated goat anti-mouse IgG antibodies； a flagellin-specific Mab (5G10) was included as a negative control, and 3D-immunized mice serum as positive control. As shown in FIG 1 (A) , 3A12, 2A10, 7A6G1 and 11F1 showed evident staining to a level comparable to the positive control, but negative control MAb 5G10 showed no staining.
Vero-1008 cells were cultured and infected as above described. Cell lysates were separated by SDS-PAGE, and transferred to PVDF membrane that was blotted by indicated antibodies following conventional western blot protocol. As shown in FIG 1 (B) , lane 1, 3A12； lane 2, 2A10； lane 3, 7A6G1； lane 4, 11F1； lane 5, 5G10 as negative control； and lane 6, positive control. The result showed that 3D protein-specific IgG mAbs (3A12, 2A10, 7A6G1 and 11F1) revealed a specific band corresponding to 3D protein, but negative control (5G10) showed no binding to 3D.
1.4. Intracellular inhibition of EV71 replication by 3D-specific IgG mAbs
Vero-1008 cells were seeded in 24-well plate at 1 × 105 cells per well and cultured for 24 hours, and then infected with EV71 at MOI ＝ 0.1. At 1 hour post-infection, cell supernatants were removed and the cells were washed 3 times. 5μg IgG antibodies diluted in OPTI-MEM was added to 100 μl OPTI-MEM with or without 5 μl Lipofectamine 2000, and the mixture was added to virus-infected cells. Then, at 3 hours post-transfection, cell supernatants were replaced with 0.5 ml DMEM with 3％ FBS. Eight hours later, EV71-infected cells were obtained and undergone one freeze-thaw cycle, and the virus titers (represented by PFU/well) in these cell samples were titrated by plaque assay. As show in FIG 2 (A) , the transfected 3A12 and 2A10 significantly reduced the virus titers； the transfected 7A6G1 reduced the virus titer, but less significant than 3A12 and 2A10； but the transfected 11F1 failed to reduce the virus titer. As for EV-5, it was a VP2-specific IgG mAb； the transfected EV-5 failed to reduce the virus titer； it was noteworthy that EV-5, when directly added into cell culture, showed increased virus titer, suggesting an effect of antibody-dependent enhancement (ADE) . The data of the virus titers demonstrated that the epitopes recognized by different 3D-specific IgG mAbs were important for their capability of inhibiting EV71 replication.
Vero-1008 cells were cultured and infected and treated with antibodies as above described except for the doses of antibodies. As shown in FIG 2 (B) , the transfected 2A10 exhibited a dose-dependent inhibitory effect on the reduction of virus titers within the tested doses (0, 0.2, 1 or 5 μg/well) , but the transfected EV-5 showed no inhibition at all tested doses. Three independent experiments were performed in duplicate, and the representative data were presented.
1.5. 3D-specific IgG mAbs inhibited in vitro 3D polymerase activities
As shown in FIG 3 (A) , there is provided a schematic diagram of 3D (RdRp) -mediated RNA elongation.
In 10 μl reaction system, the addition of 1 μg functional 3D triggered initiation and elongation of the RNA. RNA species were resolved by 15％ polyacrylamide gel electrophoresis including 7 M Urea and visualized by Stains-All staining. For inhibition assays, 2μg IgG mAbs were added in each reaction. RNA elongation activity of 3D could be determined based on the appearance of elongated RNA band. As shown in FIG 3 (B) , lane 1, negative control without polymerase； lane 2, positive control (no interventional factor) ； lane 3, 3A12； lane 4, 2A10； lane 5, 7A6G1； lane 6, 11F1； and lane 7, EV-5. 3A12, 2A10, and 7A6G significantly suppressed the appearance of the elongated RNA band, but 11F1 and EV-5 failed to suppress the appearance of the elongated RNA band. Three independent experiments were performed, and the representative data were presented.
1.6. Antiviral efficacy of 3D-specific MAbs in an in vivo murine model
Antiviral efficacy of EV71 3D-specific IgG was investigated in an in vivo murine model. 30 one-day old neonatal mice were randomly divided into 6 groups (5 mice per group) . Each group received, ip, 100 μg/50 μl 3A12, 2A10, 7A6G1, 11F1 or EV-5 IgG antibodies respectively, and PBS group was include as negative control； then each group received 103 TCID50 EV71 challenge i.p. And IgG was injected with 24-hours interval for 4 times. The mice survival data were collected each day for 2 weeks. As shown in FIG 4, 2A10-IgG and 3A12-IgG conferred 20％ or 40％ protection respectively.
1.7. In vitro virus replication with the presence of 2A10-IgG or EV-5-IgG
1 × 104 PFU EV71 were added to the consecutively diluted 200 μl mAbs (EV-5 IgG for EV71 VP2, or 2A10-IgG for EV71 3D) . The mixture infected the Caco-2 cell after 1 hour incubation. The EV71-infected Caco-2 cells were harvested, and the virus titers in these cell samples were titrated by plaque assay. As shown in FIG 5, EV-5 significantly enhanced the viral infection under the  concentrations between 0.25-16μg/ml compared with the baseline (P < 0.01) , but 2A10 did not enhance the viral infection at all tested doses.
1.8. Mapping the epitopes of EV71 3D-specific 3A12 and 2A10 and its space situation in three dimension model of EV71 3D (1RA6)
3D gene (encoded protein represented in SEQ ID NO: 15) and its truncated mutants were cloned into the pET28a expression vector, and the binding activity of IgAs to 3D protein and mutants was determined by Western blot. Furthermore, synthesized distinct lengths of peptides were used to identify the exact domain recognized by 3A12 and 2A10. As shown in Table 1, 3A12 and 2A10 recognized the polypeptides: KEPAVLTS (SEQ ID NO: 3) and YSTYVKDELRSLDKI (SEQ ID NO: 9) , respectively. An alignment of various enterovirus strains from all A, B, C and D subtypes revealed one consensus sequence KEPAVLX7X8 (SEQ ID NO: 1) recognized by 3A12, and another consensus sequence X1X2TX4VKDELRSX12X13KX15 (SEQ ID NO: 2) recognized by 2A10. As shown in FIG 6, EV71 3Dpol (1RA6) was used to indicate position of the two identified epitopes of 3A12 (orange) and 2A10 (light teal) .
Example 2
EV71 3D-specific monoclonal IgA antibodies
2.1. Generation of 3D-specific IgA mAbs
2A10-IgA and 3A12-IgA mAbs were respectively obtained by isotype switching from 2A10-IgG and 3A12-IgG mAbs following conventional isotype switching techniques.
2.2. Intracellular staining of 3D by 3D-specific IgA mAbs
VERO-C1008 cells in 24-well plate were infected with EV71 (MOI ＝ 0.1) . At 24 hours post-infection, cells were fixed with absolute methanol and processed for indirect immunofluorescence assay (IFA) using indicated 3D-specific IgA mAbs (3A12-IgA, 2A10-IgA) , negative control (16CF7-IgA against MeV) or positive control (3D-immunized mice serum) , followed by fluorescein isocyanate-conjugated goat anti-mouse IgA for determining antibody specificity against EV71.  As shown in FIG 7 (A) , 3A12-IgA and 2A10-IgA, as well as positive serum, could interact with EV71-infected cell, but negative control showed negative staining.
2.3 Western blot using 3D-specific IgA mAbs
EV71-infected VERO-C1008 cells were lysed and the cell lysates were separated by SDS-PAGE, and transferred to PVDF membrane that was blotted with 3A12-IgA, 2A10-IgA, 16CF7-IgA and positive sera. As shown in FIG 7 (B) , 3A12-IgA, 2A10-IgA and positive control, but not 16CF7-IgA, specifically stained EV71-infected cells. These results demonstrated that 3A12-IgA and 2A10-IgA mAbs maintained the 3D-specificity of 3A12-IgG and 2A10-IgG mAbs respectively.
2.4. Intracellular inhibition of EV71 replication by EV71 3D-specific IgAs via pIgR.
(i) Polarized Vero-pIgR cells were cultured in Transwell with 0.4 μm membrance and infected by EV71, allowing virus to be absorbed by the Vero-pIgR cells (virus attachment) . One hour later, Vero-pIgR cells were washed at both apical and basolateral sides to remove non-absorbed viruses. Then, 400 μl of complete DMEM was added to apical side； and 3D-specific or irrelative IgA antibodies (30 μg IgA in 110 μl) were added to the basolateral side, allowing the IgA antibodies to undergo transcytosis from basolateral side to apical side of the polarized Vero-pIgR cells. Twenty hours later, Vero-pIgR cells were washed thoroughly with PBS at both sides and scraped with 400 μl complete DMED, and the virus titers in these cell samples were titrated by plaque assay. As shown in FIG 8 (A) , both 3A12-IgA and 2A10-IgA significantly inhibited EV71 replication while 16CF7-IgA did not show inhibition.
(ii) Polarized Vero-pIgR cells were similarly operated as in (i) , but different quantities of IgA antibodies (3A12-IgA and 16CF7-IgA) were used. As shown in FIG 8 (B) , 3A12-IgA intracellularly inhibited EV71 replication in a dose-dependent manner, but 16CF7-IgA had no inhibitory effect at all tested doses.
(iii) Polarized Vero-pIgR cells were similarly operated as in (i) , but corresponding IgG antibodies (3A12-IgG, 2A10-IgG, 16CF7-IgG) were used. As  shown in FIG 8 (C) , all IgG antibodies did not show significantly inhibitory effect on EV71 replication.
(iv) Vero-pIgR cells in (i) were replaced by Vero C1008 cells. As shown in FIG 8 (D) , all three IgA antibodies (3A12-IgA, 2A10-IgA and 16CF7-IgA) showed no significant inhibitory effect on EV71 replication, indicating that IgA-mediated intracellular inhibition of EV71 replication is dependent upon the expression of pIgR on vero cell surfaces.
2.5. Intracellular inhibition of the replication of EV71 and CV strains by EV71 3D-specific IgAs
Intracellular inhibition of the replication of EV71 and CV strains was conducted as described in example 2.4. The results were summarized hereinbelow in Table 2.
Table 2. Intracellular inhibition of the replication of EV71 and CV strains
Figure PCTCN2015071021-appb-000002
where “a” denotes that “％Reducton of virus” was calculated after the percentages of virus survivals in the presence of different antibodies were calculated using the virus titers in the media alone groups as 100％.
2.6. EV71 3D-IgA inhibited viral protein expression
(i) Polarized Vero-pIgR cells were cultured in Transwell with 0.4 μm membrance and infected by EV71, allowing virus to absorb the Vero-pIgR cells (virus attachment) . One hour later, Vero-pIgR cells were washed at both apical and basolateral sides to remove non-absorbed viruses. Then, 400 μl of complete DMEM was added to apical side； and 3D-specific or irrelative IgA antibodies (30 μg IgA in 110 μl) were added to the basolateral side, allowing the IgA antibodies to undergo transcytosis from basolateral side to apical side of the polarized Vero-pIgR cells. Twenty hours later, Vero-pIgR cells were washed thoroughly with PBS at both sides and scraped with 400 μl complete DMED, and these cell samples were assessed for the quantities of proteins 3D and VP2 by western blot. As shown in FIG 9 (A) , 3A12-IgA (lane 1) and 2A10-IgA (lane 2) significantly inhibited the expression of 3D and VP2, but 16CF7-IgA (lane 3) and DMEM (lane 4) had no apparent inhibition.
(ii) Polarized Vero-pIgR cells were similarly operated as in (i) . The cell samples were analyzed by ELISA. As shown in FIG 9 (B) , 2A10-IgA and 3A12-IgA significantly inhibited the expression of 3D.
2.7. 3A12-IgA and 2A10-IgA inhibited the RNA elongation activity of 3D polymerase
In 10 μl reaction system (50 mM HEPES, 75 mM KCl, 5 mM MgCl2, 4 mM TCEP, 300 μM NTP, and 4 μM RNA Complex) , 1μg functional 3D was added to trigger initiation and elongation of the RNA. RNA species were resolved by 15％ polyacrylamide including 7 M Urea gel electrophoresis and visualized by Stains-All staining. RNA elongation activity of 3D could be judged based on the appearance of elongated RNA band. As shown in FIG 10: lane 1, negative control with no polymerase added； lane 2, positive control (no interventional factor) ； lane 3, 16CF7-IgA (2μg) ； lane 4, 2A10-IgA (2μg) ； lane 5, 3A12-IgA (2μg) . RNA elongation activity  of 3D could be judged based on the appearance of elongated RNA band. The application of MAbs IgA 2A10 and 3A12 significantly suppressed the appearance of elongated when compared with 16CF7-IgA (irrelative anti-MeV IgA) . Three independent experiments were performed, and the representative data were presented.
2.8. Evaluation of antivirus efficacy of EV71 3D-specific IgAs in a neonatal murine model
All the one day-neonatal mice received 100μg/50μl IgA i.p. followed by 1000TCID50 EV71 virus challenge i.p. And IgA was injected with 24h interval for 4 times. The mice survival data was collected each day for 3 weeks. As shown in FIG 11, 2A10-IgA and 3A12-IgA conferred 40％ and 60％ protection respectively.
Example 3
3D as an antigen
3.1. Identification of 3D in recombinant Vaccinia virus Tiantan strain expressing 3D (VTT-3D)
EV71 3D was detected in recombinant Vaccinia Virus-infected Vero cells. As shown in FIG 12, Lane 1, protein molecular weight marker, lane 2, mock infected Vero control, lane 3, VTTenv infected Vero, lane 4-7, four purified recombinant Vaccinia Virus clone-infected Vero. The infected or non-infected Vero were separated by SDS-PAGE, and transferred to PVDF membrane. 3D-specific IgG mAb 2A10-IgG was used as binding antibody. The result show that 3D gene inserted into Vaccinia Virus genome and expressed correctly in Vero cell.
3.2. Immunization program
Table 3. Immunization program
As shown in FIG 13, there is provided a schematic diagram showing the immunization protocol.
Antibody responses were assayed after each immunization: prime (FIG 14) ； first boost (FIG 15) ； second boost (FIG 16) . Each mouse in VTT-3D group received immunization of 107 PFU of virus in 100 μl, whereas each mouse in 3D group was subject to be immunized with 30 μg 3D protein in 100 μl. Serum and mucosal samples from vagina and saliva were collected and subject to determine the titer of IgA against 3D protein by ELISA.
Antibody responses were assayed in neonatal mice (FIG 17) .
3.3. Protection against EV71 challenge
After three times immunization, each neonatal mouse in VTT-3D group, 3D group, PBS groups as well as inactivated EV71 group was challenged with 103 TCID50 of virus. Neonatal mouse was observed each day. Inactivated EV71 immunization conferred complete protection of mice. All the mice in PBS negative control died in 3-5 days after challenge. As shown in FIG 18, 3D and VTT-3D conferred mice 10％-30％ protection from challenge.
Example 4
4.1. Immunization with purified 3D proteins
The expression and purification of 3D protein were described in Example 1.1. Purified 3D protein was adjuvanted with flagellin from E coli. or CTB, and then immunized mice subcutaneously (SC) , intranasally (IN) or intraperitoneally (IP) . The immunization protocol was summarized in Table 4. The intervals between two immunizations were 2 weeks； the volumes for SC and IP were 100μl, while the volumes for IN were 20μl.
Table 4. Immunization protocol with purified 3D proteins
Figure PCTCN2015071021-appb-000004
4.2. Antibody responses
2-weeks after the final immunization, sera, intestine and lung samples were collected； the intestine and lung samples were homogenized and supernatants were collected for testing. 3D-specific IgA or IgG antibody responses in these samples were titrated by ELISA. FIG 19 shows the titers of 3D-specific IgG antibodies in serum (a) , lung (b) and intestine (c) , and 3D-specific IgA antibodies in serum (d) , lung (e) and intestine (f) .
While the present invention has been described with reference to particular embodiments, it will be understood that the embodiments are illustrative and that the invention scope is not so limited. Alternative embodiments of the present invention will become apparent to those having ordinary skill in the art to which the present invention pertains. Such alternate embodiments are considered to be encompassed within the scope of the present invention. Accordingly, the scope of the present invention is defined by the appended claims and is supported by the foregoing description.

Claims (6)

  1. A monoclonal immunoglobulin A (IgA) antibody specifically binding a peptide, wherein the peptide is represented by a consensus sequence selected from the group consisting of SEQ ID NO: 1 and SEQ ID NO: 2.
  2. The monoclonal IgA antibody of claim 1, wherein the monoclonal IgA antibody binding to the peptide represented by SEQ ID NO: 1 is 3D-2A10-IgA (CCTCC NO: 2014144) , and the monoclonal IgA antibody binding to the peptide represented by SEQ ID NO: 2 is 3D-3A12-IgA (CCTCC NO: 2014142) .
  3. The monoclonal IgA antibody of claim 1, wherein the peptide represented by SEQ ID NO: 1 is selected from the group consisting of the peptides represented by SEQ ID NOS: 3-8, and the peptide represented by SEQ ID NO: 2 is selected from the group consisting of the peptides represented by SEQ ID NOS: 10-14.
  4. A composition comprising at least one first  monoclonal immunoglobulin A (IgA) antibody specifically binding to a first peptide represented by a consensus sequence of SEQ ID NO: 1, at least one second monoclonal IgA antibody specifically binding to a second peptide represented by a consensus sequence of SEQ ID NO: 2, and a pharmaceutically acceptable solution.
  5. The composition of claim 4, wherein the first monoclonal IgA antibody binding to the first peptide represented by SEQ ID NO: 1 is 3D-2A10-IgA (CCTCC NO: 2014144) , and the second monoclonal IgA antibody binding to the first peptide represented by SEQ ID NO: 2 is 3D-3A12-IgA (CCTCC NO: 2014142) .
  6. The composition of claim 4, wherein the first peptide represented by SEQ ID NO: 1 is selected from the group consisting of the peptides represented by SEQ ID NOS: 3-8, and the second peptide represented by SEQ ID NO: 2 is selected from the group consisting of the peptides  represented by SEQ ID NOS: 10-14.
PCT/CN2015/071021 2015-01-19 2015-01-19 3d protein-specific monoclonal immunoglobulin a antibodies WO2016115664A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/071021 WO2016115664A1 (en) 2015-01-19 2015-01-19 3d protein-specific monoclonal immunoglobulin a antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/071021 WO2016115664A1 (en) 2015-01-19 2015-01-19 3d protein-specific monoclonal immunoglobulin a antibodies

Publications (1)

Publication Number Publication Date
WO2016115664A1 true WO2016115664A1 (en) 2016-07-28

Family

ID=56416250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/071021 WO2016115664A1 (en) 2015-01-19 2015-01-19 3d protein-specific monoclonal immunoglobulin a antibodies

Country Status (1)

Country Link
WO (1) WO2016115664A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467015A (en) * 2023-12-27 2024-01-30 北京索莱宝科技有限公司 Antibodies, antibody combinations and uses of human IgA

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013032404A1 (en) * 2011-08-26 2013-03-07 Temasek Life Sciences Laboratory Limited Human enterovirus specific antibodies and their uses in diagnostics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013032404A1 (en) * 2011-08-26 2013-03-07 Temasek Life Sciences Laboratory Limited Human enterovirus specific antibodies and their uses in diagnostics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIENER TK ET AL.: "Characterization of a monoclonal antibody against the 3D polymerase of enterovirus 71 and its use for the detection of human enterovirus A infection", JOURNAL OF VIROLOGICAL METHODS, vol. 180, no. 1-2, 31 December 2011 (2011-12-31), pages 75 - 83 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467015A (en) * 2023-12-27 2024-01-30 北京索莱宝科技有限公司 Antibodies, antibody combinations and uses of human IgA
CN117467015B (en) * 2023-12-27 2024-03-12 北京索莱宝科技有限公司 Antibodies, antibody combinations and uses of human IgA

Similar Documents

Publication Publication Date Title
Krammer Novel universal influenza virus vaccine approaches
JP2023533772A (en) SARS-CoV-2 and influenza combination vaccine
US20230381293A1 (en) Stabilized norovirus virus-like particles as vaccine immunogens
US11103575B2 (en) Immunogenic composition for MERS coronavirus infection
Jiang et al. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice
CA2960102C (en) Flavivirus virus like particle
US12064476B2 (en) Zika virus immunogenic compositions
JP2016517440A (en) Palivizumab epitope-based virus-like particles
EP3541419A1 (en) Immunogenic composition for mers coronavirus infection
WO2021206638A1 (en) Vaccine and/or antibody for viral infection
CN113329767A (en) Adaptation of enteroviruses to VERO cells and vaccine formulations thereof
EP3463455A1 (en) Humanized antibodies against enterovirus 71
Yang et al. Immunization of mice with vaccinia virus Tiantan strain yields antibodies cross-reactive with protective antigens of monkeypox virus
Deng et al. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71
CN105085672B (en) 3D protein specific monoclonal immunoglobulin A antibodies and compositions thereof
CN105085671B (en) Monoclonal immunoglobulin G antibodies against enterovirus 3D proteins and immunogenic compositions thereof
WO2016115664A1 (en) 3d protein-specific monoclonal immunoglobulin a antibodies
WO2016115665A1 (en) Immunoglobulin g monoclonal antibodies against 3d proteins of enteroviruses
JP7145863B2 (en) Modified HSV gB protein and HSV vaccine containing same
JP2023519837A (en) Vaccine composition for treating coronavirus
Li et al. ASFV proteins presented at the surface of T7 phages induce strong antibody responses in mice
Ross et al. COBRA-based dengue tetravalent vaccine elicits neutralizing antibodies against all four dengue serotypes
Zhu et al. Dual blockages of a broad and potent neutralizing IgM antibody targeting GH loop of EV‐As
He Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies
US20240350611A1 (en) Recombinant antigen for inducing an immune response against the zika virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15878342

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15878342

Country of ref document: EP

Kind code of ref document: A1